HealthInvest Partners’s Bicara Therapeutics BCAX Stock Holding History

HealthInvest Partners’s Portfolio BCAX Stock Details BCAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.32M	Sell	145,657 -1,023,977	-88%	-$22.9M	1.16%	33
2026 Q1	$2.32M	Buy	1,169,634 +1,058,271	+950%	+$18.2M	0.75%	37
2025 Q4	$1.87M	Sell	111,363 -92,392	-45%	-$1.58M	0.6%	37
2025 Q3	$342K	Buy	203,755 +56,375	+38%	+$631K	1.27%	27
2025 Q2	$1.37M	Buy	147,380 +27,547	+23%	+$328K	0.59%	34
2025 Q1	$1.56M	Buy	+119,833	New	+$1.59M	0.69%	31

Other funds holding BCAX

RTM

Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.32B AUM 51.82% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return

HealthInvest Partners's BCAX Position: Q2 2026 in Review

HealthInvest Partners reduced its Bicara Therapeutics (BCAX) stake by 88% in Q2 2026, selling an estimated $22.9M and leaving 145,657 shares worth $4.32M. The position accounts for 1.16% of the portfolio, ranked #33.

HealthInvest Partners first reported a position in BCAX in Q1 2025 and has held it in 6 quarters since. 13 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

HealthInvest Partners held 145,657 shares of Bicara Therapeutics worth $4.32M as of Q2 2026.
HealthInvest Partners sold 1,023,977 Bicara Therapeutics shares in Q2 2026, an estimated $22.9M.
Bicara Therapeutics made up 1.16% of HealthInvest Partners's portfolio in Q2 2026, its #33 holding.
HealthInvest Partners first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 6 quarters since.
13 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on HealthInvest Partners's 13F filing for Q2 2026, filed 24 Jul 2026.